Evidence map›Paper›PMID 26316936›Full record

ReviewLung cancer international2012

Against Lung Cancer Cells: To Be, or Not to Be, That Is the Problem.

Naoko Okumura, Hitomi Yoshida, Yasuko Kitagishi, Yuri Nishimura, Shio Iseki, Satoru Matsuda

Open access · hybridAbstract readReview
In one paragraph

Review in Lung cancer international, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Naoko OkumuraDepartment of Environmental Health, Nara Women's University, Kita-Uoya Nishimachi, Nara 630-8506, Japan.
Hitomi YoshidaDepartment of Environmental Health, Nara Women's University, Kita-Uoya Nishimachi, Nara 630-8506, Japan.
Yasuko KitagishiDepartment of Environmental Health, Nara Women's University, Kita-Uoya Nishimachi, Nara 630-8506, Japan.
Yuri NishimuraDepartment of Environmental Health, Nara Women's University, Kita-Uoya Nishimachi, Nara 630-8506, Japan.
Shio IsekiDepartment of Environmental Health, Nara Women's University, Kita-Uoya Nishimachi, Nara 630-8506, Japan.
Satoru MatsudaDepartment of Environmental Health, Nara Women's University, Kita-Uoya Nishimachi, Nara 630-8506, Japan.
Nara Women's University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tobacco smoke and radioactive radon gas impose a high risk for lung cancer. The radon-derived ionizing radiation and some components of cigarette smoke induce oxidative stress by generating reactive oxygen species (ROS). Respiratory lung cells are subject to the ROS that causes DNA breaks, which subsequently bring about DNA mutagenesis and are intimately linked with carcinogenesis. The damaged cells by oxidative stress are often destroyed through the active apoptotic pathway. However, the ROS also perform critical signaling functions in stress responses, cell survival, and cell proliferation. Some molecules enhance radiation-induced tumor cell killing via the reduction in DNA repair levels. Hence the DNA repair levels may be a novel therapeutic modality in overcoming drug resistance in lung cancer. Either survival or apoptosis, which is determined by the balance between DNA damage and DNA repair levels, may lender the major problems in cancer therapy. The purpose of this paper is to take a closer look at risk factor and at therapy modulation factor in lung cancer relevant to the ROS.

Identifiers

PMID26316936
PMCPMC4437407
OpenAlexW1980145203

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.